RxDoctor Payments Data

Paul Gardial, MD

Family Medicine · Texarkana, TXNPI 1639170194

Payments from drug & device makers

$7,738in general payments, 2019–2025

Across 521 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$868
  • Lilly USA, LLC$729
  • AstraZeneca$546
  • Novo Nordisk$492
  • Boehringer Ingelheim$447
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$7,701100%
  • Education$370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,738 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$254,732
Medicare patients
424
Services billed
7,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban139$115,034
MounjaroTirzepatide96$104,350
FarxigaDapagliflozin Propanediol90$79,188
JardianceEmpagliflozin88$78,764
JanuviaSitagliptin Phosphate57$36,770
RexultiBrexpiprazole19$32,736
OzempicSemaglutide22$29,072
Tresiba Flextouch U-200Insulin Degludec23$24,443
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$24,081
RybelsusSemaglutide15$13,163
LinzessLinaclotide13$9,890
MyrbetriqMirabegron18$8,197
XareltoRivaroxaban12$8,174
Tresiba Flextouch U-100Insulin Degludec23$8,013
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$6,728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$868$115,034139 claims
Lilly USA, LLCMounjaro$729$104,35096 claims
Boehringer IngelheimJardiance, Spiriva Respimat$447$84,67999 claims
AstraZenecaFarxiga$546$79,18890 claims
Novo NordiskOzempic, Rybelsus$492$42,23537 claims
MerckJanuvia$95$36,77057 claims
Otsuka America Pharmaceutical, Inc.Rexulti$336$32,73619 claims
GSKTrelegy Ellipta$31$24,08134 claims
AbbVieLinzess, Synthroid$1,322$11,74049 claims
Astellas Pharma US IncMyrbetriq$19$8,19718 claims
Johnson & JohnsonXarelto$178$8,17412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Texarkana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →